Changes in REVEAL Lite 2 risk status are associated with long-term outcomes in patients with pulmonary arterial hypertension: A post-hoc analysis of the GRIPHON study
REVEAL Lite 2 can monitor PAH M/M risk and facilitate treatment optimization. Baseline REVEAL Lite 2 risk score was prognostic of M/M risk in patients with PAH and mediates treatment effect up to 47% for those at higher risk. Lower M/M risk with selexipag versus placebo occurred irrespective of baseline risk category (ClinicalTrials.gov identifier: NCT01106014).
Authors
- Marius M. Hoeper (ORCID: https://orcid.org/0000-0001-9086-2293)
- Victor F. Tapson (ORCID: https://orcid.org/0000-0001-9708-1457)
- Vallerie V. McLaughlin (ORCID: https://orcid.org/0000-0002-8907-1651)
- Nazzareno Galiè (ORCID: https://orcid.org/0000-0003-4271-8670)
- Seán Gaine (ORCID: https://orcid.org/0000-0002-5941-684X)
- Kelly Chin (ORCID: https://orcid.org/0000-0002-1214-6723)
- Iréne Lang (ORCID: https://orcid.org/0000-0003-0485-2692)
- Raymond L. Benza (ORCID: https://orcid.org/0000-0001-9627-6236)
- Xiaoqin Tang (ORCID: https://orcid.org/0000-0001-7749-692X)
- Olivier Sitbon (ORCID: https://orcid.org/0000-0002-1942-1951)
- Gurinderpal Doad (ORCID: https://orcid.org/0000-0002-3245-6235)
- Joseph Yen
Institutions
- Cedars-Sinai Medical Center (US)
- Université Paris-Saclay (FR)
- University of Michigan (US)
- Mater Misericordiae University Hospital (IE)
- Medizinische Hochschule Hannover (DE)
- Southwestern Medical Center (US)
- Assistance Publique – Hôpitaux de Paris (FR)
- Mount Sinai Hospital (US)
- Azienda USL di Bologna (IT)
- Bicêtre Hospital (FR)
- Southwestern Medical Center (US)
- Medical University of Vienna (AT)
- The University of Texas Southwestern Medical Center (US)
- University of Bologna (IT)
- Actelion (Switzerland) (CH)
Publication Details
- Journal
- The Journal of Heart and Lung Transplantation
- Published
- 2024-08-31
- DOI
- https://doi.org/10.1016/j.healun.2024.08.019
- Citations
- 8
- Primary Topic
- Pulmonary Hypertension Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.35
Funders
- Pfizer
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Ikaria
- United Therapeutics Corporation
- Acceleron
- Novo Nordisk
- Daiichi Sankyo Europe
- Actelion Pharmaceuticals